SITAGLIPTIN PHOSPHATE
Clinical safety rating: safe
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing their levels and prolonging their action. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner.
| Metabolism | Primarily excreted unchanged in urine (approximately 79% as parent drug). Minor metabolism via CYP3A4 and CYP2C8 to inactive metabolites. |
| Excretion | Renal excretion: ~87% (as unchanged drug in urine); biliary/fecal: ~13% (as metabolites and unchanged drug). |
| Half-life | Terminal elimination half-life: 12.4 hours (range 8–14 hours). Clinically, supports once-daily dosing with gradual onset of DPP-4 inhibition. |
| Protein binding | 38% bound (primarily to albumin). |
| Volume of Distribution | Approximately 1.65 L/kg (mean 116 L for 70 kg). Indicates wide distribution beyond extracellular fluid. |
| Bioavailability | Oral: 87% (absolute bioavailability). |
| Onset of Action | Oral: Within 1 hour post-dose (DPP-4 inhibition >80% at 1 hour). Maximal effect on incretin levels by 2–3 hours. |
| Duration of Action | Approximately 24 hours (DPP-4 inhibition >80% at 24 hours). Supports once-daily dosing; sustained glycemic control over 24 h. |
100 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | eGFR >= 45 mL/min/1.73 m2: 100 mg once daily. eGFR 30-44 mL/min/1.73 m2: 50 mg once daily. eGFR <30 mL/min/1.73 m2 or ESRD on dialysis: 25 mg once daily. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C); use with caution. |
| Pediatric use | Not approved for pediatric patients under 18 years of age. Safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment is required based on age alone. Initiate at 100 mg once daily. Monitor renal function and adjust dose as per renal adjustment guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions May cause hypersensitivity reactions including anaphylaxis.
| FDA category | Animal |
| Breastfeeding | Excreted in rat milk at a milk-to-plasma ratio of approximately 1:1. No human data; avoid breastfeeding due to potential adverse effects on infant gastrointestinal development (DPP-4 inhibition). |
| Teratogenic Risk | Pregnancy Category B. No teratogenic effects in animal studies; limited human data. First trimester: theoretical risk of fetal hyperinsulinism due to DPP-4 inhibition; second and third trimesters: avoid use due to insufficient human safety data. Consider insulin therapy for glycemic control during pregnancy. |
■ FDA Black Box Warning
None.
| Common Effects | Nasopharyngitis |
| Serious Effects |
["Type 1 diabetes mellitus","Diabetic ketoacidosis","History of hypersensitivity to sitagliptin (e.g., anaphylaxis, angioedema)"]
| Precautions | ["Pancreatitis (acute and hemorrhagic); discontinue if suspected","Hypoglycemia when used with sulfonylureas or insulin","Severe and disabling arthralgia","Bullous pemphigoid (rare)","Renal impairment: dose adjustment required for eGFR <45 mL/min","Heart failure: use with caution in patients with known risk factors"] |
Loading safety data…
| Fetal Monitoring | Monitor glycemic control via HbA1c and self-monitoring blood glucose; assess for potential fetal macrosomia and neonatal hypoglycemia if used inadvertently. No specific fetal monitoring required per manufacturer recommendations. |
| Fertility Effects | No adverse effects on fertility in animal studies. Limited human data; theoretical concern for altered ovarian function due to incretin modulation, but no clinical evidence of significant impact on fertility. |